# Cyberloq Technologies, Inc.: overview CLOQ · OTC · CIK 1437517 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cloq.md) · [Financials](/companies/cloq/financials.md) · [Filings](/companies/cloq/filings.md) · [Insiders](/companies/cloq/insiders.md) Latest reported revenue: [$0](/filings/0001493152-26-010037.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-010037). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0 d](/filings/0001493152-25-023235.md) | [0.0 d](/filings/0001493152-26-010037.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001493152-25-023235.md) | not reported | [0.00](/filings/0001493152-26-023656.md) | [0.00](/filings/0001493152-26-039220.md) | [0.00](/filings/0001493152-25-023235.md) | not reported | [0.00](/filings/0001493152-26-023656.md) | [0.00](/filings/0001493152-26-039220.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.2](/filings/0001493152-23-009418.md) | [2.7](/filings/0001493152-24-011921.md) | [16.0](/filings/0001641172-25-001165.md) | [15.0](/filings/0001493152-26-010037.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(538311.2%)](/filings/0001493152-23-009418.md) | [(25546.1%)](/filings/0001493152-24-011921.md) | [(2296.3%)](/filings/0001641172-25-001165.md) | [(5019.5%)](/filings/0001493152-26-010037.md) | not reported | | Net margin | % | [(552138.1%)](/filings/0001493152-23-009418.md) | [(36654.7%)](/filings/0001493152-24-011921.md) | [(6418.6%)](/filings/0001641172-25-001165.md) | [(6596.3%)](/filings/0001493152-26-010037.md) | not reported | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-22-008545.md) | [0.01](/filings/0001493152-24-011921.md) | [(0.01)](/filings/0001641172-25-001165.md) | [(0.01)](/filings/0001493152-26-010037.md) | [(0.01)](/filings/0001493152-26-010037.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cloq/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Comprehensive Financial Planning, Inc./PA](/funds/2044855.md) | 2026-06-30 | $1.1k | 8,624 | | Unchanged | ## Recent filings [All 162 filings](/companies/cloq/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 00:36 ET | [8-K](/filings/0001493152-26-045402.md) | 1.01 Entry into a material agreement | 0001493152-26-045402 | | 2026-09-16 | 20:58 ET | [8-K](/filings/0001493152-26-042937.md) | 1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-042937 | | 2026-08-19 | 20:27 ET | [10-Q](/filings/0001493152-26-039220.md) | Quarterly report, period 2026-06-30 | 0001493152-26-039220 | | 2026-05-15 | 19:34 ET | [10-Q](/filings/0001493152-26-023656.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023656 | | 2026-03-13 | 19:36 ET | [10-K](/filings/0001493152-26-010037.md) | Annual report, period 2025-12-31 | 0001493152-26-010037 | | 2026-02-26 | 21:40 ET | [8-K](/filings/0001493152-26-008185.md) | 1.01 Entry into a material agreement | 0001493152-26-008185 | | 2025-11-14 | 17:49 ET | [10-Q](/filings/0001493152-25-023235.md) | Quarterly report, period 2025-09-30 | 0001493152-25-023235 | | 2025-08-13 | 18:17 ET | [10-Q](/filings/0001641172-25-023402.md) | Quarterly report, period 2025-06-30 | 0001641172-25-023402 | | 2025-06-02 | 18:44 ET | [8-K](/filings/0001641172-25-013227.md) | 3.03 Change to security holders’ rights | 0001641172-25-013227 | | 2025-05-13 | 20:33 ET | [10-Q](/filings/0001641172-25-009976.md) | Quarterly report, period 2025-03-31 | 0001641172-25-009976 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010037.md), filed Mar 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1437517 - Tickers: CLOQ - Exchange: OTC - SIC code: 7372 Services-Prepackaged Software - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.